key: cord-0697262-6953m8sa
authors: Giron, L. B.; Dweep, H.; Yin, X.; Wang, H.; Damra, M.; Goldman, A. R.; Gorman, N.; Palmer, C. S.; Tang, H.-Y.; Shaikh, M. W.; Forsyth, C. B.; Balk, R. A.; Zilberstein, N. F.; Liu, Q.; Kossenkov, A.; Keshavarzian, A.; Landay, A.; Abdel-Mohsen, M.
title: Severe COVID-19 Is Fueled by Disrupted Gut Barrier Integrity
date: 2020-11-16
journal: nan
DOI: 10.1101/2020.11.13.20231209
sha: 36d439ae2c348457693301b51beaea779ff774db
doc_id: 697262
cord_uid: 6953m8sa

A disruption of the crosstalk between gut microbiota and the lung (gut-lung axis) has been implicated as a driver of severity during respiratory-related diseases. Lung injury causes systemic inflammation, which disrupts gut barrier integrity, increasing the permeability to gut microbes and their products. This exacerbates inflammation, resulting in positive feedback. To test the possibility that a disrupted gut contributes to Coronavirus disease 2019 (COVID-19) severity, we used a systems biology approach to analyze plasma from COVID-19 patients with varying disease severity and controls. Severe COVID-19 is associated with a dramatic increase in tight junction permeability and translocation of bacterial and fungal products into blood. This intestinal disruption and microbial translocation correlate strongly with increased systemic inflammation and complement activation, lower gut metabolic function, and higher mortality. Our study highlights a previously unappreciated factor with significant clinical implications, disruption in gut barrier integrity, as a force that contributes to COVID-19 severity.

Coronavirus Disease 2019 , the disease caused by severe acute respiratory syndrome 2 coronavirus 2 (SARS-CoV-2) infection, can manifest with diverse clinical presentations. While 3 the majority of infected individuals exhibit asymptomatic or mild respiratory tract infection, a 4 significant population, especially those who are older or suffering from pre-existing metabolic-5 associated diseases, face severe manifestations such as acute respiratory distress syndrome 6 (ARDS), multi-organ failure, and death. [1] [2] [3] [4] [5] A state of hyper-inflammation and hyperactivated 7 immune responses, characterized by an ensuing cytokine storm and increased complement 8 activation, has been associated with COVID-19 severity. 1,6-10 However, the pathophysiological 9 mechanisms that contribute to these phenomena remain mostly unknown. Understanding these 10 mechanisms is a crucial step in designing rational clinical and therapeutic strategies. 11

A disruption of the crosstalk between gut microbiota and the lung (gut-lung axis) has been 12 implicated as a driver of severity during respiratory-related diseases, including ARDS. 11-14 13 Systemic inflammation caused by a lung infection or injury can lead to a disruption of the gut 14 barrier integrity and increase the permeability to gut microbes and microbial products. This 15 microbial translocation can exacerbate systemic inflammation and lung injury -resulting in 16 positive feedback. [11] [12] [13] [14] In addition, SARS-CoV2 can directly infect gut cells, 15 and viral infections 17 of the gut cause changes in gut structure 16 and breakdown of the epithelial barrier. 17, 18 Such 18 disruption of the gut-lung axis is more likely to occur in older individuals and individuals with 19 metabolic-and/or aging-associated diseases, as these individuals often experience changes in the 20 composition of the gut microbiota (microbial dysbiosis), 19, 20 which facilitate a higher susceptibility 21 to falling into the vicious cycle between microbial translocation and systemic inflammation. 21-24 22 Even as microbial translocation impacts systemic inflammation directly, it may also impact it 23 indirectly by modulating circulating levels of gut-and gut microbiota-associated products such as 24 metabolites and lipids. Plasma metabolites and lipids can reflect the functional status of the gut 25 and the metabolic activity of its microbiota. [25] [26] [27] [28] They also are biologically active molecules in 26 their own right, regulating several immunological functions, including inflammatory 27 responses. 29, 30 A third class of microbial products that can translocate from the gut is glycan-28 degrading enzymes. Glycans on circulating glycoproteins and antibodies (IgGs and IgAs) are 29 . CC-BY-NC-ND 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. (which was not certified by peer review) preprint

The copyright holder for this this version posted November 16, 2020. ; https://doi.org/10.1101/2020.11.13.20231209 doi: medRxiv preprint essential for regulating several immunological responses, including complement activation. 31 The 30

glycan-degrading enzymes are released by several members of the gut microbiome and their 31 translocation can alter the circulating glycome, leading to higher inflammation and complement 32 activation. 32 Indeed, altered glycosylation of plasma glycoproteins (including immunoglobulin G, 33 IgG) has been associated with the onset and progression of inflammatory bowel disease (IBD). 32-34 37 Furthermore, modulation of the gut microbiota via fecal microbiota transplantation affects IgG 35 and serum glycosylation. 38 Here, we hypothesized that a vicious cycle between SARS- CoV2 36 infection, systemic inflammation, disrupted intestinal barrier integrity, and microbial translocation 37 contributes to COVID-19 severity. 38

To test this hypothesis, we applied a multi-omic systems biology approach to analyze plasma 39 samples from 60 COVID-19 patients with varying disease severity and 20 age-controlled (most 40 were 50 to 65 years old) and gender-matched (~50% female) SARS-CoV2 negative controls. We 41 investigated the potential links between gut barrier integrity, microbial translocation, systemic 42 inflammation, and COVID-19 severity. Our data indicate that severe COVID-19 is associated with 43 a dramatic increase in tight junction permeability and translocation of bacterial and fungal products 44 into the blood. This disrupted intestinal barrier integrity and microbial translocation correlates 45 strongly with increased systemic inflammation, increased immune activation, decreased intestinal 46 function, disrupted plasma metabolome and glycome, and higher mortality rate. 47 molecules that can directly impact immunological and inflammatory responses. Therefore, we 165 sought to identify links between the 35 dysregulated gut-associated plasma metabolites ( Table 1) Table 5 ); out 180 of these 24 classes, 16 were significantly (FDR<0.05) modulated by severe COVID-19 (11 were 181 downregulated whereas five were upregulated) (Figure 5b) . Pathway analysis of this severe-182 COVID-19-associated lipidomic signature showed that glycerophospholipid and choline 183 metabolism were the most significantly dysregulated pathways (Figure 5c ). The gut microbiota is 184 heavily involved in these two interconnected pathways. 51 Gut microbial dysbiosis can alter the 185 digestion and absorption of glycerophospholipids, leading to several diseases. 51 We first observed a significant (FDR<0.05) glycomic alteration during severe COVID-19 in levels 208 of IgA glycans, plasma N-glycans, plasma total glycans, and IgG glycans (Figure 6a) . These 

variables whose combination associates with the risk of hospitalization during COVID-19. Our 219 data thus far support the hypothesis that gut dysfunction fuels COVID-19 severity. We sought to 220 examine whether markers of tight junction permeability and microbial translocation 221 Table 2 ) can distinguish between hospitalized COVID-19 patients (moderate 222 and severe groups combined) and non-hospitalized individuals (mild and controls combined). We 223 . CC-BY-NC-ND 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. (which was not certified by peer review) preprint

The copyright holder for this this version posted November 16, 2020. ; https://doi.org/10.1101/2020.11.13.20231209 doi: medRxiv preprint applied the machine learning algorithm Lasso (least absolute shrinkage and selection operator) 224 regularization to select markers with the highest ability to distinguish between the two groups. The 225 analysis employed samples with complete data sets (n=79; one sample did not have complete data). 226

Lasso selected zonulin, LBP, and sCD14 as the three markers to be included in a multivariable 227 logistic regression model that distinguishes hospitalized from non-hospitalized individuals with 228 area under the ROC curve (AUC) of 99.23% (Figure 7a ; 95% confidence interval: 98.1% -100%). 229

This value was higher than the AUC values obtained from logistic models using each variable 230 individually ( Table 2) . 231

Next, we used the multivariable logistic model to estimate a risk score of hospitalization for each 232 individual. We then examined the ability of these risk scores to classify hospitalized from non-233 . CC-BY-NC-ND 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. (which was not certified by peer review) preprint

The copyright holder for this this version posted November 16, 2020. ; https://doi.org/10.1101/2020.11.13.20231209 doi: medRxiv preprint

We used a systems biology approach to provide multiple layers of evidence that severe COVID-245 19 is associated with a disruption in intestinal barrier integrity, higher microbial translocation, and 246 intestinal dysfunction. These data highlight a previously unappreciated factor, disruption in gut 247 barrier integrity, as a force that likely fuels COVID-19 severity. Our results do not imply that COVID-19 may also be on a path towards long term consequences due to persistent, microbial 269 translocation. Thus, understanding the long-term implications of the disrupted gut function that we 270 observed during severe COVID-19 should be a clinical priority. An accompanying priority should 271 be to consider how to modify clinical practice to prevent or reduce gut disruption. Currently, for 272 . CC-BY-NC-ND 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. (which was not certified by peer review) preprint

The copyright holder for this this version posted November 16, 2020. ; https://doi.org/10.1101/2020.11.13.20231209 doi: medRxiv preprint example, a large number of patients are receiving antibiotic therapy during their COVID-19 273 treatment. 1, 5 However, massive use of antibiotics can alter gut microbiota and gut function, leading 274 to higher susceptibility to inflammatory disorders. 64 Thus, for any clinical practices that alter the 275 gut, their overall impact on disease course should be carefully considered, especially for older 276 patients and those with metabolic diseases, who are likely to have a lower threshold for intestinal 277 dysfunction. 278

Our study raises the possibility that some of the markers we identified through our multi-omic 279 approach may be able to predict the risk of disease progression if measured immediately after 280 diagnosis. The plasma is a pool of biological molecules, including polar metabolites, lipids, and 281 glycoproteins, secreted or shed from multiple tissues. Thus, the levels of these molecules likely 282

indicate the overall status of multiple organs, making them excellent candidates for biomarker 283 discovery. Indeed, various plasma metabolites and glycomic features of plasma glycoproteins have 284 been investigated as biomarkers for several diseases, including IBD, diabetes, cardiovascular 285 diseases, and cancer. [65] [66] [67] [68] [69] [70] [71] In addition, markers of intestinal barrier permeability have been used as 286 predictors of multiple organ dysfunction during critical illness. 72 The striking differences we 287 observed in the levels of specific metabolites, lipids, and glycoproteins between COVID-19 288 disease states suggests they may also have value for risk prediction or therapeutic response. Future 289 longitudinal, controlled studies will be needed to assess these possibilities. 290

Our study also reveals several potential therapeutic targets for severe COVID-19, including 291 zonulin. Zonulin is the only known physiological modulator of the intestinal tight junctions. 73 

Microbial dysbiosis and translocation enhance zonulin release, which in turn induces tight junction 293 permeability, leading to more microbial translocation. This microbial translocation triggers 294 inflammation, which promotes further gut leakiness. 40, 41 Increased intestinal permeability and 295 serum zonulin levels have been observed during many inflammatory diseases, including Crohn's 296 disease and celiac disease. 74, 75 Preventing zonulin-mediated increase in intestinal permeability by 297 a zonulin receptor antagonist AT1001 (larazotide acetate) decreased the severity and incidence of 298 several inflammation-associated diseases in pre-clinical and clinical studies. [76] [77] [78] [79] [80] [81] [82] The strikingly 299 high level of serum zonulin we observed during severe COVID-19, which were associated with 300 inflammation and mortality, raise the question of whether modulators of tight junction 301 permeability (such as with AT-1001) can lessen COVID-19 severity. 302 . CC-BY-NC-ND 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. (which was not certified by peer review) preprint

The copyright holder for this this version posted November 16, 2020. ; https://doi.org/10.1101/2020.11.13.20231209 doi: medRxiv preprint Another question is whether there is a genetic predisposition to intestinal barrier permeability and 303 COVID-19 severity. Zonulin is the uncleaved precursor to haptoglobin (HP). 73 There are two 304 common alleles for haptoglobin, HP1 and HP2. Individuals with the HP2 allele produce high levels 305 of zonulin, whereas individuals with the HP1 allele do not. 41 High-zonulin-producers (HP2 allele) 306 are more likely to develop IBD 83,84 and experience morbidity from inflammatory diseases. 85, 86 The 307 worldwide frequency of each haptoglobin phenotype varies by region. 84, 87 How the HP genotype 308 and zonulin polymorphisms 88 are linked to severe COVID-19 and associated mortality should be 309 the subject of future studies. 310

A second potential therapeutic target revealed by this work is citrulline. Citrulline levels were 311 reduced in both moderate and severe COVID-19, and the citrulline metabolism and biosynthesis 312 pathways were among the top metabolic pathways disrupted in severe COVID-19. Citrulline is an 313 intermediate in arginine metabolism, 89 and a marker of gut and enterocyte function. 25, 90 Disrupted 314 citrulline metabolism, as we observed during severe COVID-19, has been associated with 315 microbial dysbiosis and dysregulated intestinal function. 91 In addition to its role as a biomarker, 316 citrulline has an important role in preserving gut barrier function. In an intestinal obstruction 317 mouse model, pretreatment with a citrulline-rich diet preserved gut barrier integrity. 92 Thus, our 318 data, and the work of others from diverse fields, suggest that greater understanding of the 319 interaction between the gut, intestinal microbiota, and amino acid metabolism during COVID-19 320 might inform pharmaceutical and diet approaches to improve COVID-19 outcomes. Second, galactosylated glycans on circulating antibodies link Dectin-1 on phagocytes to FcγRIIB 333 . CC-BY-NC-ND 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. (which was not certified by peer review) preprint

The copyright holder for this this version posted November 16, 2020. ; https://doi.org/10.1101/2020.11.13.20231209 doi: medRxiv preprint on myeloid cells to prevent the inflammation mediated by complement activation. 31 Loss of 334 galactose, as observed during COVID-19, decreases the opportunity to activate this important anti-335 complement activation checkpoint, thereby promoting inflammation. As using highly-336 galactosylated immune complexes can prevent inflammation mediated by complement 337 activation, 31 these and similar glycomic approaches may represent another therapeutic opportunity 338 to reduce inflammation during COVID-19. 339

Caveats of our study include the sample size and sampling of blood. As noted above, correcting 340 for potential confounders will require larger cohorts from varying geographic and demographic 341 settings. Independent test sets and samples from non-COVID1-9 hospitalized and ICU-admitted 342 patients will also be needed. In addition, longitudinal analyses will be required to examine the 343 long-term implications of our findings and their potential value as prognostic biomarkers. Analysis 344 of gut biopsies, stool, and bronchial lavage will be needed to determine the precise contributions 345 of the gut-lung axis in COVID-19. Finally, mechanistic studies in vitro and in animal models of 346

In summary, while this study was exploratory in nature, our data strongly suggest for the first time: 349

(1) severe COVID-19 is associated with disrupted intestinal barrier integrity, higher microbial 350 translocation, and gut dysfunction; (2) severe COVID-19 is associated with a dramatic shift in 351 levels of several biologically active molecules, which likely contribute to disease severity by 352 inducing inflammation. Our study is beginning to shed light on the potentially critical role of a 353 previously unappreciated factor, disruption of intestinal barrier integrity, in the pathophysiology 354 of severe COVID-19. By understanding these unappreciated underpinnings of COVID-19, this 355 work may serve to identify biomarkers for risk stratification and build a foundation for developing 356 strategies to prevent or reduce the severity of COVID- 19. 357 . CC-BY-NC-ND 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. (Figure 1a) . Individuals were selected to have a median age between 52.5 to 58.5 years. 364

The study cohort was also chosen to have a 35 to 60% representation of female gender per disease 365 status group (Supplementary Table 1 ). Eight participants of the cohort (two from the moderate 366 group and six from the severe group) died from COVID-19 (Supplementary Table 1 were measured using DuoSet ELISA kits (R&D Systems; catalog # DY1707, # DY1152-05, # 386 . CC-BY-NC-ND 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. (which was not certified by peer review) preprint were identified by accurate mass and retention time using an in-house database generated from 406 pure standards or by MS2 spectra using the mzCloud spectral database (mzCloud.org) and 407 selecting the best matches with scores of 50 or greater. Metabolite quantification used peak areas 408 from full MS runs and were corrected based on the periodic QC runs. 409

Untargeted measurement of plasma lipids. Lipidomics analysis was performed as described 410

previously. 101 Briefly, plasma samples were spiked with EquiSplash mix (Avanti Polar Lipids). 411

Lipids were extracted with 2:1:1 chloroform: methanol: 0.8% sodium chloride. Samples were 412 resuspended in 1:9 chloroform: methanol after drying the organic phase under nitrogen. LC-MS 413 runs were performed on a Thermo Scientific Q Exactive HF-X mass spectrometer with HESI II 414 probe and Vanquish Horizon UHPLC system. Reversed-phase liquid chromatography was 415 performed at 0.35 ml/min on an Accucore C30 column (2.1 mm x 150 mm, ThermoFisher 416 . CC-BY-NC-ND 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. (which was not certified by peer review) preprint

The copyright holder for this this version posted November 16, 2020. ; https://doi.org/10.1101/2020.11.13.20231209 doi: medRxiv preprint Scientific) at 50°C. Solvent A was 50:50 acetonitrile: water, and solvent B was 88:10:2 417 isopropanol: acetonitrile: water solvents. Both solvents contained 5 mM ammonium formate and 418 0.1% formic acid. The gradient was 0% B for 3 min, 0% to 60% B over 7 min, 60% to 85% B over 419 10 min, 85% to 100% B over 10 min, 100% B for 5 min, 100% to 0% B over 0.01 min, and 0% B 420 Table 6 ) and IgG N-glycans into 22 peaks (Supplementary Table 7 Table 1 Spearman's rank correlation tests were used for statistical analysis. FDR was calculated using Benjamini-Hochberg method.

. CC-BY-NC-ND 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity.

The copyright holder for this this version posted November 16, 2020. ; https://doi.org/10.1101/2020.11.13.20231209 doi: medRxiv preprint Table 4 : List of the gut-associated and gut microbiota-associated metabolites detected in our study using untargeted LC-MS/MS (50 of the 278 metabolites identified in plasma).

The two thousand fifteen lipids identified in this study were assigned to 24 lipid classes. Table 6 . The structures and names of N-glycans identified in plasma by capillary electrophoresis. These glycan structures can be grouped into 15 groups: bisecting GlcNAc (B group), sialic acid (non-siaylated (S0), mono-sialylated (S1), di-sialylated (S2), tri-sialylatedand (S3), tetra-sialylated (S4), and total sialylated (ST)), galactose (agalactosylated (G0), monogalactosylated (G1), di-galactosylated (G2), and total galactosylated (GT)), core fucose (FC group), branched fucose (FB group), high branched (HB group), and low branch (LB group). Table 7 . The structures and names of N-glycans identified in IgG by capillary electrophoresis. These glycan structures were grouped into 9 groups, depending on the presence or absence of four key monosaccharides: bisecting GlcNAc (B group), sialic acid (mon-sialylated (S1), di-sialylated (S2), and total siaylated (ST)), terminal galactose (agalactosylated (G0), monogalactosylated (G1), di-galactosylated (G2), and total galactose (GT)), and fucose (F group).

. CC-BY-NC-ND 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. (which was not certified by peer review) preprint

The copyright holder for this this version posted November 16, 2020. ; https://doi.org/10.1101/2020.11.13.20231209 doi: medRxiv preprint Supplementary Table 8 . Lectins used in the 45-plex lectin microarray and their glycan-binding specificity.

. CC-BY-NC-ND 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. 

The authors have no competing interests.

. CC-BY-NC-ND 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. . CC-BY-NC-ND 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. . CC-BY-NC-ND 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. . CC-BY-NC-ND 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. (which was not certified by peer review) preprint . CC-BY-NC-ND 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. (which was not certified by peer review) preprint . CC-BY-NC-ND 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. (which was not certified by peer review) preprint . CC-BY-NC-ND 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. (which was not certified by peer review) preprint . CC-BY-NC-ND 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. (which was not certified by peer review) preprint

The copyright holder for this this version posted November 16, 2020. ; https://doi.org/10.1101/2020.11.13.20231209 doi: medRxiv preprint . CC-BY-NC-ND 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. . CC-BY-NC-ND 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. . CC-BY-NC-ND 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. (which was not certified by peer review) preprint

The copyright holder for this this version posted November 16, 2020. ;

. CC-BY-NC-ND 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. . CC-BY-NC-ND 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. (which was not certified by peer review) preprint

The copyright holder for this this version posted November 16, 2020. ; https://doi.org/10.1101/2020.11.13.20231209 doi: medRxiv preprint

Tateno, H., Kuno, A., Itakura, Y. & Hirabayashi, J. A versatile technology for cellular glycomics using lectin microarray. Methods in enzymology 478, 181-195 (2010) .

. CC-BY-NC-ND 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. (which was not certified by peer review) preprint

The copyright holder for this this version posted November 16, 2020. ; https://doi.org/10.1101/2020.11.13.20231209 doi: medRxiv preprint

Trbojevic Akmacic, I., et al. Inflammatory bowel disease associates with proinflammatory potential of the immunoglobulin G glycome. Inflamm Bowel Dis 21, 1237-1247 (2015).

. CC-BY-NC-ND 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. . CC-BY-NC-ND 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. (which was not certified by peer review) preprint

The copyright holder for this this version posted November 16, 2020. ; https://doi.org/10.1101/2020.11.13.20231209 doi: medRxiv preprint Figure 1 . CC-BY-NC-ND 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. (which was not certified by peer review) preprint

The copyright holder for this this version posted November 16, 2020. ; https://doi.org/10.1101/2020.11.13.20231209 doi: medRxiv preprint Figure 2 . CC-BY-NC-ND 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. (which was not certified by peer review) preprint

The copyright holder for this this version posted November 16, 2020. ; https://doi.org/10.1101/2020.11.13.20231209 doi: medRxiv preprint . CC-BY-NC-ND 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. (which was not certified by peer review) preprint

The copyright holder for this this version posted November 16, 2020. ; https://doi.org/10.1101/2020.11.13.20231209 doi: medRxiv preprint . CC-BY-NC-ND 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. (which was not certified by peer review) preprint

The copyright holder for this this version posted November 16, 2020. ; https://doi.org/10.1101/2020.11.13.20231209 doi: medRxiv preprint . CC-BY-NC-ND 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. (which was not certified by peer review) preprint Table 2 . Logistic regression models of tight junction permeability and microbial translocation markers for their ability to distinguish hospitalized from non-hospitalized individuals.

Bold variables are variables selected by Lasso to be included in the multivariable logistic model; AUC = Area under the ROC Curve; SE = Standard error

Clinical Characteristics of Coronavirus Disease 2019 in China

Mild or Moderate Covid-19

Baseline Characteristics and Outcomes of 1591 Patients Infected With SARS-CoV-2 Admitted to ICUs of the Lombardy Region

Presenting Characteristics, Comorbidities, and Outcomes Among 5700 Patients Hospitalized With COVID-19 in the New York City Area

Epidemiological and clinical characteristics of 99 cases of 2019 novel coronavirus pneumonia in Wuhan, China: a descriptive study

Imbalanced Host Response to SARS-CoV-2 Drives Development of COVID-19

Clinical and immunological features of severe and moderate coronavirus disease 2019

COVID-19: consider cytokine storm syndromes and immunosuppression

Clinical features of patients infected with 2019 novel coronavirus in Wuhan

Complement as a target in COVID-19?

The role of the lung microbiota and the gut-lung axis in respiratory infectious diseases

More of the Gut in the Lung: How Two Microbiomes Meet in ARDS

Enrichment of the lung microbiome with gut bacteria in sepsis and the acute respiratory distress syndrome

SARS-CoV-2 productively infects human gut enterocytes

CD4+ T cell depletion during all stages of HIV disease occurs predominantly in the gastrointestinal tract

Tight junctions/adherens junctions: basic structure and function

Intestinal mucosal barrier function in health and disease

Gut microbiota and aging

Age-Associated Microbial Dysbiosis Promotes Intestinal Permeability, Systemic Inflammation, and Macrophage Dysfunction

Gut microbiota lipopolysaccharide accelerates inflamm-aging in mice

Aged Gut Microbiota Contributes to Systemical Inflammaging after Transfer to Germ-Free Mice

Structural modulation of gut microbiota in life-long calorie-restricted mice

Pathogenesis of Parkinson disease--the gut-brain axis and environmental factors

Biological and clinical significance of haptoglobin polymorphism in humans

Abnormal changes of plasma acute phase proteins in schizophrenia and the relation between schizophrenia and haptoglobin (Hp) gene

Almost all about citrulline in mammals

Assessment of small bowel function in critical illness: potential role of citrulline metabolism

The Microbiome, Intestinal Function, and Arginine Metabolism of Healthy Indian Women Are Different from Those of American and Jamaican Women

Pretreatment with citrulline improves gut barrier after intestinal obstruction in mice

Galectin-3 is involved in HIV-1 expression through NF-kappaB activation and associated with Tat in latently infected cells

The role of galectins in virus infection -A systemic literature review

Galectin-9 Mediates HIV Transcription by Inducing TCR-Dependent ERK Signaling

Galectin-3 Enhances Avian H5N1 Influenza A Virus-Induced Pulmonary Inflammation by Promoting NLRP3 Inflammasome Activation

Regulation of transforming growth factor-beta1-driven lung fibrosis by galectin-3. American journal of respiratory and critical care medicine 185

A potential role for Galectin-3 inhibitors in the treatment of COVID-19

Immunopathology of galectin-3: an increasingly promising target in COVID-19

The mitophagy effector FUNDC1 controls mitochondrial reprogramming and cellular plasticity in cancer cells

Changes in Aged Fibroblast Lipid Metabolism Induce Age-Dependent Melanoma Cell Resistance to Targeted Therapy via the Fatty Acid Transporter FATP2

Microbial aromatic acid metabolites formed in the gut account for a major fraction of the polyphenols excreted in urine of rats fed red wine polyphenols

Microbial Phenolic Metabolites: Which Molecules Actually Have an Effect on Human Health?

Glucuronides in the gut: Sugar-driven symbioses between microbe and host

Insights into the metabolism and microbial biotransformation of dietary flavan-3-ols and the bioactivity of their metabolites

Hydroxycinnamic acids and human health: recent advances

Host-Gut Microbiota Metabolic Interactions

Metabolomics in diabetes, a review

Valeric Acid, a Gut Microbiota Product, Penetrates to the Eye and Lowers Intraocular Pressure in Rats

Metabolic tinkering by the gut microbiome: Implications for brain development and function

Assessment of urinary 3-indoxyl sulfate as a marker for gut microbiota diversity and abundance of Clostridiales

Anaerobic 4-hydroxyproline utilization: Discovery of a new glycyl radical enzyme in the human gut microbiome uncovers a widespread microbial metabolic activity

The microbiome: A key regulator of stress and neuroinflammation

Abnormal metabolism of gut microbiota reveals the possible molecular mechanism of nephropathy induced by hyperuricemia

The Relationship between Choline Bioavailability from Diet, Intestinal Microbiota Composition, and Its Modulation of Human Diseases

Butyrate and propionate production from D-mannitol in the large intestine of pig and rat

An untargeted fecal and urine metabolomics analysis of the interplay between the gut microbiome, diet and human metabolism in Indian and Chinese adults

Mechanisms Linking the Gut Microbiome and Glucose Metabolism

Gut microbiome-derived metabolites modulate intestinal epithelial cell damage and mitigate graft-versus-host disease

Bile acids and the gut microbiome

Deoxycholic Acid-Induced Gut Dysbiosis Disrupts Bile Acid Enterohepatic Circulation and Promotes Intestinal Inflammation

Adaptation of the Gut Microbiota to Modern Dietary Sugars and Sweeteners

Clinical Characteristics of Coronavirus Disease 2019 in China

Mild or Moderate Covid-19

Baseline Characteristics and Outcomes of 1591 Patients Infected With SARS-CoV-2 Admitted to ICUs of the Lombardy Region

Presenting Characteristics, Comorbidities, and Outcomes Among 5700 Patients Hospitalized With COVID-19 in the New York City Area

Epidemiological and clinical characteristics of 99 cases of 2019 novel coronavirus pneumonia in Wuhan, China: a descriptive study

Imbalanced Host Response to SARS-CoV-2 Drives Development of COVID-19

Clinical and immunological features of severe and moderate coronavirus disease 2019

COVID-19: consider cytokine storm syndromes and immunosuppression

Clinical features of patients infected with 2019 novel coronavirus in Wuhan

Complement as a target in COVID-19?

The role of the lung microbiota and the gut-lung axis in respiratory infectious diseases

The Role of the Microbiome in Asthma: The Gut(-)Lung Axis

More of the Gut in the Lung: How Two Microbiomes Meet in ARDS

Enrichment of the lung microbiome with gut bacteria in sepsis and the acute respiratory distress syndrome

SARS-CoV-2 productively infects human gut enterocytes

CD4+ T cell depletion during all stages of HIV disease occurs predominantly in the gastrointestinal tract

Tight junctions/adherens junctions: basic structure and function

Intestinal mucosal barrier function in health and disease

Gut microbiota and aging

Age-Associated Microbial Dysbiosis Promotes Intestinal Permeability, Systemic Inflammation, and Macrophage Dysfunction

Gut microbiota lipopolysaccharide accelerates inflamm-aging in mice

Aged Gut Microbiota Contributes to Systemical Inflammaging after Transfer to Germ-Free Mice

Structural modulation of gut microbiota in life-long calorie-restricted mice

Pathogenesis of Parkinson disease--the gut-brain axis and environmental factors

Citrulline as a marker of intestinal function and absorption in clinical settings: A systematic review and meta-analysis. United

Genetics, and the Gut Microbiome Drive Dynamic Changes in Plasma Metabolites

Gut Microbial Associations to Plasma Metabolites Linked to Cardiovascular Phenotypes and Risk

Exploration of the microbiota and metabolites within body fluids could pinpoint novel disease mechanisms

Nicotinamide reduces inflammation and oxidative stress via the cholinergic system in fructose-induced metabolic syndrome in rats

Anti-inflammatory activity of IgG1 mediated by Fc galactosylation and association of FcgammaRIIB and dectin-1

Efficient utilization of complex N-linked glycans is a selective advantage for Bacteroides fragilis in extraintestinal infections

Glycosylation of Immunoglobulin G Associates With Clinical Features of Inflammatory Bowel Diseases

The pathogenic role of Bacteroides vulgatus in patients with ulcerative colitis

Sialic acid catabolism drives intestinal inflammation and microbial dysbiosis in mice

Characterization of antibody responses against rectal mucosa-associated bacterial flora in patients with ulcerative colitis

Commensal Bacteroides species induce colitis in host-genotypespecific fashion in a mouse model of inflammatory bowel disease

Decreased Complexity of Serum N-glycan Structures Associates with Successful Fecal Microbiota Transplantation for Recurrent Clostridioides difficile Infection

Zonulin and its regulation of intestinal barrier function: the biological door to inflammation, autoimmunity, and cancer

Host-dependent zonulin secretion causes the impairment of the small intestine barrier function after bacterial exposure

Zonulin as a potential putative biomarker of risk for shared type 1 diabetes and celiac disease autoimmunity

Essential roles of CD14 and lipopolysaccharide-binding protein for activation of toll-like receptor (TLR)2 as well as TLR4 Reconstitution of TLR2-and TLR4-activation by distinguishable ligands in LPS preparations

Serum (1-->3)-beta-D-glucan levels in HIV-infected individuals are associated with immunosuppression, inflammation, and cardiopulmonary function

Plasma Levels of C-Type Lectin REG3alpha and Gut Damage in People With Human Immunodeficiency Virus

Effect of microflora on the free amino acid distribution in various regions of the mouse gastrointestinal tract

Dietary Amino Acids and the Gut-Microbiome-Immune Axis: Physiological Metabolism and Therapeutic Prospects

Effects of amino acid-derived luminal metabolites on the colonic epithelium and physiopathological consequences

A nutritive view on the host-pathogen interplay

IDO expression by dendritic cells: tolerance and tryptophan catabolism

Dysbiosis of the gut microbiota is associated with HIV disease progression and tryptophan catabolism

Modulation of the Gut Microbiota during High-Dose Glycerol Monolaurate-Mediated Amelioration of Obesity in Mice Fed a High-Fat Diet

Intestinal Crosstalk between Bile Acids and Microbiota and Its Impact on Host Metabolism

Alterations Of Glycerophospholipid And Fatty Acyl Metabolism In Multiple Brain Regions Of Schizophrenia Microbiota Recipient Mice

Phosphatidylcholine and lysophosphatidylcholine in intestinal mucus of ulcerative colitis patients. A quantitative approach by nanoElectrospray-tandem mass spectrometry

Manifestations and prognosis of gastrointestinal and liver involvement in patients with COVID-19: a systematic review and meta-analysis

Clinical Characteristics of COVID-19 Patients With Digestive Symptoms in Hubei, China: A Descriptive, Cross-Sectional, Multicenter Study

Gastrointestinal involvement attenuates COVID-19 severity and mortality. medRxiv

The long-term impact of severe acute respiratory syndrome on pulmonary function, exercise capacity and health status

Altered Lipid Metabolism in Recovered SARS Patients Twelve Years after Infection

HIV and the gut microbiota, partners in crime: breaking the vicious cycle to unearth new therapeutic targets

Altered metabolism of gut microbiota contributes to chronic immune activation in HIV-infected individuals

Intestinal microbiota, microbial translocation, and systemic inflammation in chronic HIV infection

Antibiotics promote inflammation through the translocation of native commensal colonic bacteria

Rapid and noninvasive diagnosis of the presence and severity of coronary heart disease using 1H-NMR-based metabonomics

A Review on MS-Based Blood Biomarkers for Alzheimer's Disease

Towards personalized diagnostics via longitudinal study of the human plasma N-glycome

Increased plasma N-glycome complexity is associated with higher risk of type 2 diabetes

IgG Glycome in Colorectal Cancer

A novel protein glycan biomarker and future cardiovascular disease events

Increased intestinal permeability is associated with the development of multiple organ dysfunction syndrome in critically ill ICU patients

Identification of human zonulin, a physiological modulator of tight junctions, as prehaptoglobin-2

Zonulin, a newly discovered modulator of intestinal permeability, and its expression in coeliac disease

Zonulin, a regulator of epithelial and endothelial barrier functions, and its involvement in chronic inflammatory diseases

Reducing small intestinal permeability attenuates colitis in the IL10 gene-deficient mouse

Larazotide acetate in patients with coeliac disease undergoing a gluten challenge: a randomised placebo-controlled study

A randomized, double-blind study of larazotide acetate to prevent the activation of celiac disease during gluten challenge

Targeting zonulin and intestinal epithelial barrier function to prevent onset of arthritis

Role of the intestinal tight junction modulator zonulin in the pathogenesis of type I diabetes in BB diabetic-prone rats

Larazotide acetate for persistent symptoms of celiac disease despite a gluten-free diet: a randomized controlled trial

The safety, tolerance, pharmacokinetic and pharmacodynamic effects of single doses of AT-1001 in . CC-BY-NC-ND 4.0 International license It is made available under a coeliac disease subjects: a proof of concept study

Effects of haptoglobin polymorphisms and deficiency on susceptibility to inflammatory bowel disease and on severity of murine colitis

Haptoglobin polymorphism: a novel genetic risk factor for celiac disease development and its clinical manifestations

Haptoglobin genotype: a determinant of cardiovascular complication risk in type 1 diabetes

The Haptoglobin genotype predicts cardio-renal mortality in type 1 diabetes

Biological and clinical significance of haptoglobin polymorphism in humans

Abnormal changes of plasma acute phase proteins in schizophrenia and the relation between schizophrenia and haptoglobin (Hp) gene

Almost all about citrulline in mammals

Assessment of small bowel function in critical illness: potential role of citrulline metabolism

The Microbiome, Intestinal Function, and Arginine Metabolism of Healthy Indian Women Are Different from Those of American and Jamaican Women

Pretreatment with citrulline improves gut barrier after intestinal obstruction in mice

Galectin-3 is involved in HIV-1 expression through NF-kappaB activation and associated with Tat in latently infected cells

The role of galectins in virus infection -A systemic literature review

Galectin-9 Mediates HIV Transcription by Inducing TCR-Dependent ERK Signaling

Galectin-3 Enhances Avian H5N1 Influenza A Virus-Induced Pulmonary Inflammation by Promoting NLRP3 Inflammasome Activation

Regulation of transforming growth factor-beta1-driven lung fibrosis by galectin-3. American journal of respiratory and critical care medicine 185

A potential role for Galectin-3 inhibitors in the treatment of COVID-19

Immunopathology of galectin-3: an increasingly promising target in COVID-19

The mitophagy effector FUNDC1 controls mitochondrial reprogramming and cellular plasticity in cancer cells

Changes in Aged Fibroblast Lipid Metabolism Induce Age-Dependent Melanoma Cell Resistance to Targeted Therapy via the Fatty Acid Transporter FATP2

Microbial aromatic acid metabolites formed in the gut account for a major fraction of the polyphenols excreted in urine of rats fed red wine polyphenols

Microbial Phenolic Metabolites: Which Molecules Actually Have an Effect on Human Health?

Glucuronides in the gut: Sugar-driven symbioses between microbe and host

Insights into the metabolism and microbial biotransformation of dietary flavan-3-ols and the bioactivity of their metabolites

Hydroxycinnamic acids and human health: recent advances

Host-Gut Microbiota Metabolic Interactions

Metabolomics in diabetes, a review

Valeric Acid, a Gut Microbiota Product, Penetrates to the Eye and Lowers Intraocular Pressure in Rats

Metabolic tinkering by the gut microbiome: Implications for brain development and function

Assessment of urinary 3-indoxyl sulfate as a marker for gut microbiota diversity and abundance of Clostridiales

Anaerobic 4-hydroxyproline utilization: Discovery of a new glycyl radical enzyme in the human gut microbiome uncovers a widespread microbial metabolic activity

The microbiome: A key regulator of stress and neuroinflammation

Abnormal metabolism of gut microbiota reveals the possible molecular mechanism of nephropathy induced by hyperuricemia

The Relationship between Choline Bioavailability from Diet, Intestinal Microbiota Composition, and Its Modulation of Human Diseases

Butyrate and propionate production from D-mannitol in the large intestine of pig and rat

An untargeted fecal and urine metabolomics analysis of the interplay between the gut microbiome, diet and human metabolism in Indian and Chinese adults

Mechanisms Linking the Gut Microbiome and Glucose Metabolism

Gut microbiome-derived metabolites modulate intestinal epithelial cell damage and mitigate graft-versus-host disease

Bile acids and the gut microbiome

Deoxycholic Acid-Induced Gut Dysbiosis Disrupts Bile Acid Enterohepatic Circulation and Promotes Intestinal Inflammation

Adaptation of the Gut Microbiota to Modern Dietary Sugars and Sweeteners

Contribution of gut microbiota to metabolism of dietary glycine betaine in mice and in vitro colonic fermentation

Perturbation by Bestatin of Glycyl-l-leucine Absorption in Isolated Epithelial Cells from Rat Intestine

Gut microbial metabolites as multi-kingdom intermediates

Association between metabolic profile and microbiomic changes in rats with functional dyspepsia

Metabolic phenotypes and the gut microbiota in response to dietary resistant starch type 2 in normal-weight subjects: a randomized crossover trial

Macronutrient metabolism by the human gut microbiome: major fermentation by-products and their impact on host health

Phenylalanine ammonia-lyase, a key component used for phenylpropanoids production by metabolic engineering

Long-Term Changes in Gut Microbial Metabolite Trimethylamine N-Oxide and Coronary Heart Disease Risk

CC-BY-NC-ND 4.0 International license It is made available under a